Qiagen マネジメント

マネジメント基準チェック /44

Qiagenの CEO はThierry Bernardで、 Oct2019年に任命され、の在任期間は 4.5年です。の年間総報酬は$ 1.99Mで、 49.1%給与と50.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.11%を直接所有しており、その価値はCHF 8.92M 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と9.8年です。

主要情報

Thierry Bernard

最高経営責任者

US$2.0m

報酬総額

CEO給与比率	49.1%
CEO在任期間	4.5yrs
CEOの所有権	0.1%
経営陣の平均在職期間	6.3yrs
取締役会の平均在任期間	9.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Qiagen の収益と比較して、Thierry Bernard の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	US$2m	US$979k	US$341m
Sep 30 2023	n/a	n/a	US$485m
Jun 30 2023	n/a	n/a	US$490m
Mar 31 2023	n/a	n/a	US$505m
Dec 31 2022	US$10m	US$950k	US$423m
Sep 30 2022	n/a	n/a	US$488m
Jun 30 2022	n/a	n/a	US$539m
Mar 31 2022	n/a	n/a	US$563m
Dec 31 2021	US$2m	US$900k	US$513m
Sep 30 2021	n/a	n/a	US$311m
Jun 30 2021	n/a	n/a	US$480m
Mar 31 2021	n/a	n/a	US$449m
Dec 31 2020	US$2m	US$900k	US$359m
Sep 30 2020	n/a	n/a	US$191m
Jun 30 2020	n/a	n/a	US$14m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$1m	US$650k	-US$41m

報酬と市場: Thierryの総報酬 ($USD 1.99M ) は、 Swiss市場 ($USD 1.99M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Thierryの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Thierry Bernard (58 yo)

4.5yrs

在職期間

US$1,991,874

報酬

Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board since 2021 and had been its Interim Chief Executive Officer since Octo...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Thierry Bernard	CEO, MD & Member of Management Board	4.5yrs	US$1.99m	0.11% CHF 8.9m
Roland Sackers	CFO, MD & Member of Management Board	20.3yrs	US$1.07m	0.16% CHF 13.4m
Antonio Santos	Senior VP & Head of Global Operations	2yrs	データなし	データなし
John Gilardi	Vice President of Corporate Communications & Investor Relations	13.5yrs	データなし	データなし
Stephany Foster	Senior VP & Head of Human Resources	4.5yrs	データなし	データなし
Thomas Schweins	Senior Vice President of Life Science Business Area	6.3yrs	データなし	データなし
Thomas Theuringer	Senior Director & Head of External Communications	no data	データなし	データなし
Jean-Pascal Viola	Senior VP & Head of Molecular Diagnostics Business Area	8.9yrs	データなし	データなし
Jonathan Sheldon	Senior Vice President of Qiagen Digital Insights Business Area	6.3yrs	データなし	データなし

6.3yrs

平均在職期間

52.5yo

平均年齢

経験豊富な経営陣: QIAの経営陣は経験豊富で経験豊富です（平均在職期間は6.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Metin Colpan	Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board	20.3yrs	US$86.50k	0.19% CHF 15.8m
Elizabeth Tallett	Independent Member of the Supervisory Board	12.8yrs	US$101.50k	0.022% CHF 1.8m
Eva Pisa	Independent Member of the Supervisory Board	1.8yrs	US$68.50k	データなし
Lawrence Rosen	Independent Chairman of Supervisory Board	10.8yrs	US$188.50k	0.0067% CHF 567.8k
Toralf Haag	Independent Member of the Supervisory Board	3.3yrs	US$82.50k	0.0012% CHF 100.3k
Elaine Mardis	Independent Member of the Supervisory Board	9.8yrs	US$79.50k	0.0019% CHF 155.9k
Rick Bright	Member of Scientific Advisory Board	no data	データなし	データなし
Peter Kaspar	Member of the Scientific Advisory Board	no data	データなし	データなし
Ross Levine	Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board	8.3yrs	US$68.50k	0.0076% CHF 636.9k
Patrice Nordmann	Member of the Scientific Advisory Board	no data	データなし	データなし
Neville Sanjana	Member of the Scientific Advisory Board	no data	データなし	データなし
Sarah Polonius-Teichmann	Member of the Scientific Advisory Board	no data	データなし	データなし

9.8yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: QIAの取締役会は経験豊富であると考えられます ( 9.8年の平均在任期間)。

Qiagen マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Qiagen N.V., Annual General Meeting, Jun 21, 2024

CFO, MD & Member of Management Board recently sold CHF1.2m worth of stock

Board Member recently sold CHF200k worth of stock

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

CFO, MD & Member of Management Board recently sold CHF1.5m worth of stock

Qiagen N.V., Annual General Meeting, Jun 23, 2022

Recent updates

Qiagen Collaborates with McGill University to Advance Microbiome Research

Qiagen N.V. Reaffirms Earnings Guidance for the Full Year 2024

QIAGEN Receives FDA Clearance of QIAstat-Dx Meningitis/Encephalitis Panel to Support Emergency Diagnostics

QIAGEN Receives FDA Clearance for QIAstat-Dx Mini Panel to Improve Precision in Outpatient Respiratory Treatment

QIAGEN Expands Automated Liquid Biopsy Portfolio to Enhance Oncology, Prenatal Care and Organ Transplant Applications

Qiagen N.V. to Report Q3, 2024 Results on Nov 06, 2024

QIAGEN N.V. Launches QIAcuityDx Digital PCR System for Clinical Testing in Oncology

QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

Qiagen N.V. to Report First Half, 2024 Results on Aug 16, 2024

Qiagen N.V. Updates Earnings Guidance for the Full Year 2024

Qiagen N.V. to Report Q2, 2024 Results on Jul 31, 2024

Qiagen to Discontinue NeuMoDx Integrated PCR Testing System

Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care

Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine

QIAGEN Receives European IVDR Certification for QIAGEN Clinical Insight Interpret

Qiagen Receives FDA Clearance for Qiastat-Dx Respiratory Syndromic Testing Panel for Fast and Accurate Results

Qiagen N.V., Annual General Meeting, Jun 21, 2024

QIAGEN Announces the Availability of QCI Secondary Analysis

Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024

QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use

Qiagen N.V. to Report Q1, 2024 Results on Apr 29, 2024

Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024

Full year 2023 earnings released: EPS: US$1.53 (vs US$2.61 in FY 2022)

Qiagen N.V. Provides Earnings Guidance for Year 2024

Qiagen N.V. to Report Q4, 2023 Results on Feb 06, 2024

Qiagen N.V. Receives FDA Clearance of NeuMoDx CT/NG Assay for Use on Both Neumodx 96 and 288 Molecular Systems

QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation

QIAGEN Launches New QIAcuity Digital PCR Kits and Updated Software to Expand Use by Biopharma and Food Safety Customers

Qiagen Launches Complete Sample to Insight Workflow for Microbiome Research

Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 3Q 2022)

Qiagen N.V. to Report Q3, 2023 Results on Oct 30, 2023

QIAGEN Launches QuantiFERON-EBV RUO Assay, Facilitating Research of Cell-Mediated Immune Response to Epstein-Barr Virus

QIAGEN Extends AI Capabilities of its NGS interpretation Software QCI Interpret to Enable Clinical Exome Completeness

QIAGEN Enhances QIAwave Portfolio with New Nucleic Acid Extraction Kits

CFO, MD & Member of Management Board recently sold CHF1.2m worth of stock

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.42 in 2Q 2022)

Qiagen N.V. Revises Earnings Guidance for the Full Year 2023

Qiagen N.V. to Report Q2, 2023 Results on Aug 08, 2023

QIAGEN’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-Analysis of Tuberculosis Screening

Qiagen N.V. Provides Earnings Guidance for the Year 2023

Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook

Full year 2022 earnings released: EPS: US$2.53 (vs US$2.36 in FY 2021)

Board Member recently sold CHF200k worth of stock

Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021)

Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021)

Qiagen N.V. Provides Sales Guidance for the Full Year 2023

Qiagen Reportedly Weighs Sale of Minority Stake in its Bioinformatics Division

Qiagen N.V. to Report Q4, 2022 Results on Feb 07, 2023

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. from Telegraph Hill Partners and 1315 Capital, LLC for approximately $150 million.

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. for $150 million.

QIAGEN Receives U.S. Food and Drug Administration Approval for Companion Diagnostic to Mirati Therapeutics' Krazati in Non-Small Cell Lung Cancer

Qiagen N.V. Launches Monkeypox Test for NeuMoDx Platform to Fight Global Outbreak by Boosting Research and Surveillance

Third quarter 2022 earnings released: EPS: US$0.36 (vs US$0.58 in 3Q 2021)

Qiagen N.V. Revises Earnings Guidance for the Year 2022

Qiagen N.V. to Report Q3, 2022 Results on Nov 07, 2022

Qiagen N.V. Announces New Additions to its Comprehensive NeuMoDx Assay Menu for Organ Transplant-Associated Viruses

QIAGEN N.V. Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Second quarter 2022 earnings released: EPS: US$0.42 (vs US$0.53 in 2Q 2021)

QIAGEN Adds New Biopharma Products to QIAcuity Digital PCR Portfolio and Launches Expert Custom Assay Design Service

Qiagen N.V. Raises Earnings Guidance for the Full Year 2022

Qiagen N.V. to Report Q2, 2022 Results on Jul 27, 2022

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

CFO, MD & Member of Management Board recently sold CHF1.5m worth of stock

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

Qiagen N.V., Annual General Meeting, Jun 23, 2022

First quarter 2022 earnings released: EPS: US$0.68 (vs US$0.57 in 1Q 2021)

Qiagen N.V. Revises Net Sales Guidance for the Full Year 2022

Qiagen N.V. to Report Q1, 2022 Results on Apr 27, 2022

マネジメント基準チェック /44